Risk of prevalent human papillomavirus (HPV) infection by quartiles of alcohol intake stratified by lifetime number of sexual partners*
| By lifetime number of sexual partners | |||
|---|---|---|---|
| 0–1 (N =719) | 2–9 (N= 302 ) | ≥10 (N=288 ) | |
| HPV status | mPR† | mPR† | mPR† |
| Any HPV | |||
| Q1–Q3 | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
| Q4 | 1.14 (1.00–1.29) | 1.17 (0.96–1.44) | 1.16 (1.01–1.33) |
| Oncogenic | |||
| Q1–Q3 | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
| Q4 | 1.36 (1.09–1.70) | 1.41 (0.93–2.12) | 1.32 (0.90–1.96) |
| Non-oncogenic | |||
| Q1–Q3 | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
| Q4 | 1.21 (0.87–1.69) | 1.96 (1.09–3.51) | 1.32 (0.79–2.20) |
| HPV 6, 11, 16 or 18‡ | |||
| Q1–Q3 | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
| Q4 | 1.58 (1.11–2.25) | 1.58 (0.93–2.67) | 1.30 (0.76–2.26)§ |
Bold font indicates a statistically significant HR.
*Alcohol intake was categorised by the quartile intake values among HPV-negative men and the first three quartiles were combined for the referent category. Lifetime number of sexual partners was defined as men who have sex with women and/or men.
†Adjusted for age, race, smoking status, ethnicity and circumcision unless otherwise noted.
‡HPV 6, 11, 16 or 18 are the quadrivalent vaccine HPV types.
§Because of small sample size, we could not adjust for race. Adjusted for age, smoking status, ethnicity and circumcision.
mPR, multivariable prevalence ratio; Qn, quartile.